身体活动,阿尔茨海默氏症血生物标志物和认知能力
Seung Ae Kim1,2, Daeun Shin3, Hongki Ham3,4,5,6
1Department of Neurology, Seoul National University Hospital, Seoul, South Korea.
JAMA network open
|March 5, 2025
概括
定期体力活动 (PA) 与关键阿尔茨海默氏症的较低水平有关.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 生物标志物研究 生物标志物研究
背景情况:
- 身体活动 (PA) 是一种潜在的非药物干预措施,用于预防痴呆.
- 胰腺和阿尔茨海默病 (AD) 血生物标志物之间的关系尚不清楚.
研究的目的:
- 检查身体活动水平,血生物标志物 (Aβ42/40,ptau217,GFAP,NfL) 和认知功能之间的关联.
- 在有或没有认知障碍的个体中探索这些关联.
主要方法:
- 来自韩国记忆诊所的1144名参与者的横截面研究.
- 使用国际体育活动问卷评估的体育活动,并分为四分位数.
- 测量了等离子体生物标志物和认知评估 (MMSE,CDR-SB).
主要成果:
- 较高的体力活动四分位数与较低的血ptau217和NfL水平有关.
- 增加的体力活动与更好的认知得分相关 (更高的MMSE,更低的CDR-SB).
- 在老年人和认知障碍患者中,相关性更强.
结论:
- 身体活动可能通过影响神经退行和病理学来延缓认知衰退.
- 研究结果表明,PA可能是预防阿尔茨海默病的可修改因素.
- 需要进行纵向研究来确定因果关系.
更多相关视频
06:34Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model
Published on: June 2, 2023
1.1K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.1K
相关概念视频
Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145
Dementia
87
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
87
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
92
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
92
Cognitive Development During Adulthood
43
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
43
